CD24 and cancer: Specifically, from a prospective cohort of women with BI-RADS 4 breast lesions, we used TENPO to isolate both HER2+ EVs and CD24+ EVs and then performed next generation miRNA sequencing on each isolate to identify EV miRNA biomarkers that distinguish cancer versus noncancer patient samples.